Document is current

Any future updates will be listed below

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Crossref DOI link: https://doi.org/10.1186/s12967-019-1803-9

Published Online: 2019-02-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark